World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
99
Citations
42215
World Ranking
8500
National Ranking
259

Research.com Recognitions

  • 2005 - Fellow of the American Association for the Advancement of Science (AAAS)

Overview

Pascal Hammel is affiliated with the University of Paris-Saclay in France. Their research primarily centers on medicine, with a significant focus on oncology and cancer-related fields. The main fields of study represented in their publications include Medicine and Biochemistry, Genetics and Molecular Biology. Subfields of particular emphasis are Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Surgery, and Epidemiology.

Their work addresses several key topics: pancreatic and hepatic oncology research, cancer genomics and diagnostics, renal cell carcinoma treatment, neuroendocrine tumor research advances, gastric cancer management and outcomes, cholangiocarcinoma and gallbladder cancer studies, and cancer immunotherapy and biomarkers.

Pascal Hammel has contributed research articles to a variety of prominent publication venues. Frequent journals include:

  • Journal of Clinical Oncology
  • Therapeutic Advances in Medical Oncology
  • Annals of Oncology
  • European Journal of Cancer
  • Pancreatology

Recent papers authored by or involving Pascal Hammel cover a range of topics related to cancer treatment and genetics:

  • Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer, 2022, JAMA Oncology
  • Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study, 2020, The Lancet. Gastroenterology & Hepatology
  • Clinical practice guidelines for BRCA1 and BRCA2 genetic testing, 2021, European Journal of Cancer
  • A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma, 2020, Annals of Oncology
  • Activation of lysosomal iron triggers ferroptosis in cancer, 2025, Nature

Collaboration is a notable aspect of Pascal Hammel's research activities. Frequent co-authors include:

  • Jean-Baptiste Bachet
  • Jérôme Cros
  • Anthony Turpin
  • Cindy Neuzillet
  • Rémy Nicolle

Among distinctions received, Pascal Hammel was recognized as a Fellow of the American Association for the Advancement of Science (AAAS) in 2005.

Best Publications

  • Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

    Eric Raymond;Laetitia Dahan;Jean Luc Raoul;Yung Jue Bang

  • FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

    Thierry Conroy;Pascal Hammel;Mohamed Hebbar;Meher Ben Abdelghani

  • Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

    John P. Neoptolemos;John P. Neoptolemos;Daniel H. Palmer;Daniel H. Palmer;Paula Ghaneh;Eftychia E. Psarelli

  • Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer

    Talia Golan;Pascal Hammel;Michele Reni;Eric Van Cutsem

  • Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial

    Christophe Louvet;R. Labianca;P. Hammel;G. Lledo

  • Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib the LAP07 randomized clinical trial

    Pascal Hammel;Florence Huguet;Jean-Luc van Laethem;David Goldstein

  • Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study

    B. Chauffert;F. Mornex;Franck Bonnetain;P. Rougier

  • nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial

    David Goldstein;Robert Hassan El-Maraghi;Pascal Hammel;Volker Heinemann

  • Impact of Chemoradiotherapy After Disease Control With Chemotherapy in Locally Advanced Pancreatic Adenocarcinoma in GERCOR Phase II and III Studies

    Florence Huguet;Thierry André;Pascal Hammel;Pascal Artru

  • Regression of Liver Fibrosis after Biliary Drainage in Patients with Chronic Pancreatitis and Stenosis of the Common Bile Duct

    Pascal Hammel;Anne Couvelard;Dermot O'Toole;Anne Ratouis

  • Risk of pancreatic adenocarcinoma in chronic pancreatitis

    D Malka;P Hammel;F Maire;P Rufat

  • Intraductal papillary mucinous tumors of the pancreas confined to secondary ducts show less aggressive pathologic features as compared with those involving the main pancreatic duct.

    B Terris;P Ponsot;F Paye;P Hammel

  • Pancreatic involvement in von Hippel–Lindau disease

    Pascal R. Hammel;Valerie Vilgrain;Benoit Terris;Alfred Penfornis

  • Value of endoscopic ultrasound guided fine needle aspiration biopsy in the diagnosis of solid pancreatic masses

    M Voss;P Hammel;G Molas;L Palazzo

  • Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study

    Julien Edeline;Meher Benabdelghani;Aurélie Bertaut;Jérôme Watelet

  • Risk factors for diabetes mellitus in chronic pancreatitis

    David Malka;Pascal Hammel;Alain Sauvanet;Pierre Rufat

  • Assessment of complications of EUS-guided fine-needle aspiration.

    Dermot O'Toole;Laurent Palazzo;Ramuntçho Arotçarena;Alain Dancour

  • Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial

    David Malka;Pascale Cervera;Stéphanie Foulon;Tanja Trarbach

  • First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials

    Harpreet S Wasan;Peter Gibbs;Navesh K Sharma;Julien Taieb

  • The natural history of hereditary pancreatitis : a national series

    V. Rebours;M. C. Boutron-Ruault;M. Schnee;C. Ferec

Frequent Co-Authors

Philippe Ruszniewski
Philippe Ruszniewski Université Paris Cité
Alain Sauvanet
Alain Sauvanet Université Paris Cité
Anne Couvelard
Anne Couvelard Université Paris Cité
Eric Raymond
Eric Raymond St. Joseph Hospital
Valérie Vilgrain
Valérie Vilgrain Université Paris Cité
Thierry André
Thierry André Université Paris Cité
Jacques Belghiti
Jacques Belghiti Beaujon Hospital
David Goldstein
David Goldstein University of New South Wales
Bengt Glimelius
Bengt Glimelius Uppsala University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

The medical field offers diverse career options beyond the traditional MD path, and online education makes these pathways more accessible than ever. For those seeking advanced nursing roles, pursuing one of the most affordable online dnp programs can be a practical way to achieve a Doctor of Nursing Practice degree and move into leadership or specialized clinical positions.

Aspiring pharmacists can benefit from online pharm d programs, which allow students to earn a Doctorate in Pharmacy with greater flexibility, making it easier to balance studies with work or family commitments.

For those interested in healthcare administration or data management, earning a health information management degree online equips graduates with the skills to oversee medical data, compliance, and information systems vital to today's health organizations.

Additionally, starting with specialized credentials such as a medical coding certification online offers a quick entry point into the healthcare sector, providing vital support to healthcare providers by ensuring proper billing and insurance processing.

Best Scientists Citing Pascal Hammel

Trending Scientists

Recently Published Articles